

Jaundice in the Newborn – Hyperbilirubinemia

Jaundice in the Newborn – Hyperbilirubinemia

MNCY supported the development of the Jaundice in the Newborn (hyperbilirubinemia) screening, assessment and treatment for well newborns (greater than 35 weeks of age at birth), clinical practice guideline in 2019. This guideline assists the clinical teams to reduce the incidence of **severe hyperbilirubinemia** and related consequences in otherwise healthy term and late preterm newborns by:

- identifying newborns at risk for hyperbilirubinemia;
- identifying newborns with hyperbilirubinemia in a timely and accurate manner;
- providing timely interventions and/or treatment(s) as required; and
- ensuring appropriate follow-up in the **community** after hospital discharge.

MNCY has begun work with clinical experts on the management of jaundice in newborns under the age of 35 weeks of age at birth. Once this work is complete a review of the original pathway will be undertaken.

For more information, please email maternalnewbornchildyouth.scn@ahs.ca.

June 2022



Insert document title • 2